7:35AM NuPathe reports smaller-than-expected Q4 net loss (PATH) 4.50 : NuPathe reports Q4 EPS of ($0.38) vs ($0.49) Capital IQ Consensus Estimate; the co continues to believe it will be able to address all of the questions raised in the CRL for its migraine patch (NP101) in a timely fashion. NuPathe remains on track to resubmit its NDA in 1H12 and expects the resubmission will result in a six-month review by the Agency.
Market Data 
Markets 
AI
